We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Phibro Animal Health Corporation (PAHC - Free Report) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 21.9% year over year. Adjusted EPS also surpassed the Zacks Consensus Estimate of 35 cents. According to the company, the year-over-year improvement was primarily driven by a higher gross profit ratio, reduced interest expense and a lower effective income tax rate.
Including one-time items, the company reported EPS of 38 cents, in line with the year-ago quarter.
Full-year adjusted earnings came in at $1.51, an increase of 5.6% from year-ago period. Also, the figure surpassed the Zacks Consensus Estimate of $1.45.
Net Sales
In the reported quarter, Phibro’s net sales were $194.8 million, up 2.9% year over year. The improvement was driven by sales growth in the Animal Health, Mineral Nutrition segment and Performance Products.
Fiscal 2017 registered net sales of $764.3 million, up 12.8% from a year ago. Also, revenues beat the Zacks Consensus Estimate of $761.52 million.
Phibro Animal Health Corporation Price, Consensus and EPS Surprise
Net sales at the Animal Health segment increased 2% to $128.6 million in the reported quarter on the back of volume increases in the nutritional specialty and vaccine product groups within the segment. While nutritional specialty products grew 14%, sales from vaccines increased 8%, principally on volume growth of products for poultry and swine industries.
However, sales at Medicated feed additives (MFAs) and Other fell 3% primarily due to volume declines.
Domestic net sales of MFAs and Other declined $7.4 million due to reduced volumes of medically important antimicrobials. International net sales increased by $5.2 million, driven by growth in the Asia-Pacific region, which is partially offset by declines in Brazil due to economic conditions.
Net sales at the Mineral Nutrition segment increased 5% to $52.8 million on increased volumes and higher average selling prices resulting from underlying raw material commodity price increase.
Net sales at the Performance Products segment increased 6% to $13.4 million. This was driven by higher volumes of copper-based products and personal care ingredients and increased average selling prices of copper-based products. However, the increase was partially offset by lower average selling prices of personal care ingredients.
Operational Update
Phibro’s fiscal fourth-quarter gross profit increased 5.9% year over year to $63.1 million. The gross margin expanded 89 basis points (bps) to 32.4%.
Selling, general and administrative expenses rose 0.3% to $39.6 million. Operating margin expanded 144 bps year over year to 12.1% in the quarter.
Financial Update
Year to date, Phibro generated $98.4 million in cash flow from operations compared with $37.2 million in the year-ago period. Capital expenditure amounted to $20.9 million in this period, reflecting a reduction from $36.4 million in fiscal 2016.
FY18 Outlook
Phibro provided its fiscal 2018 guidance. The company currently expects to generate net sales of $765-$790 million. The current Zacks Consensus Estimate of $777.1 million falls within the guided range.
Phibro provided its adjusted EPS guidance in the range of $1.55–$1.61. The current Zacks Consensus Estimate of $1.55 is at the lower end of the company's guided range.
Our Take
Phibro ended the fiscal fourth quarter on a solid note with both net sales and adjusted earnings beating the Zacks Consensus Estimate. Also, the year-over-year increase on both the fronts is encouraging. Further, the company witnessed year-over-year improvement across all segments. We are also encouraged by the expansion in the gross and operating margin in the reported quarter.
Moreover, on a full-year basis, adjusted earnings and net sales have surpassed the Zacks Consensus Estimate as well with year-over-year increases in both.
The company has provided its fiscal 2018 guidance for both net sales and adjusted earnings.
Zacks Rank & Peer Performance
Phibro currently has a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , PetMed Express, Inc. (PETS - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while PetMed and IDEXX carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences’ second-quarter 2017 adjusted earnings improved 42.1% year over year, primarily driven by strong sales growth at the company’s transcatheter heart valves business. The stock has gained around 3.5% over the last three months.
IDEXX Laboratories recorded second-quarter 2017 EPS of 95 cents, up 28% (up 30% at CER year over year on a reported basis. Moreover, revenues rose 9% year over year (10% on organic basis) to $509 million.
PetMed reported earnings per share of 45 cents for the first quarter of fiscal 2018, up 40.6% from the year-ago quarter’s 32 cents. Moreover, net sales in the reported quarter rose 9.9% year over year to $79.7 million.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Image: Bigstock
Phibro Animal (PAHC) Beats Q4 Earnings & Sales Estimates
Phibro Animal Health Corporation (PAHC - Free Report) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 21.9% year over year. Adjusted EPS also surpassed the Zacks Consensus Estimate of 35 cents. According to the company, the year-over-year improvement was primarily driven by a higher gross profit ratio, reduced interest expense and a lower effective income tax rate.
Including one-time items, the company reported EPS of 38 cents, in line with the year-ago quarter.
Full-year adjusted earnings came in at $1.51, an increase of 5.6% from year-ago period. Also, the figure surpassed the Zacks Consensus Estimate of $1.45.
Net Sales
In the reported quarter, Phibro’s net sales were $194.8 million, up 2.9% year over year. The improvement was driven by sales growth in the Animal Health, Mineral Nutrition segment and Performance Products.
Fiscal 2017 registered net sales of $764.3 million, up 12.8% from a year ago. Also, revenues beat the Zacks Consensus Estimate of $761.52 million.
Phibro Animal Health Corporation Price, Consensus and EPS Surprise
Phibro Animal Health Corporation Price, Consensus and EPS Surprise | Phibro Animal Health Corporation Quote
Sales by Segments
Net sales at the Animal Health segment increased 2% to $128.6 million in the reported quarter on the back of volume increases in the nutritional specialty and vaccine product groups within the segment. While nutritional specialty products grew 14%, sales from vaccines increased 8%, principally on volume growth of products for poultry and swine industries.
However, sales at Medicated feed additives (MFAs) and Other fell 3% primarily due to volume declines.
Domestic net sales of MFAs and Other declined $7.4 million due to reduced volumes of medically important antimicrobials. International net sales increased by $5.2 million, driven by growth in the Asia-Pacific region, which is partially offset by declines in Brazil due to economic conditions.
Net sales at the Mineral Nutrition segment increased 5% to $52.8 million on increased volumes and higher average selling prices resulting from underlying raw material commodity price increase.
Net sales at the Performance Products segment increased 6% to $13.4 million. This was driven by higher volumes of copper-based products and personal care ingredients and increased average selling prices of copper-based products. However, the increase was partially offset by lower average selling prices of personal care ingredients.
Operational Update
Phibro’s fiscal fourth-quarter gross profit increased 5.9% year over year to $63.1 million. The gross margin expanded 89 basis points (bps) to 32.4%.
Selling, general and administrative expenses rose 0.3% to $39.6 million. Operating margin expanded 144 bps year over year to 12.1% in the quarter.
Financial Update
Year to date, Phibro generated $98.4 million in cash flow from operations compared with $37.2 million in the year-ago period. Capital expenditure amounted to $20.9 million in this period, reflecting a reduction from $36.4 million in fiscal 2016.
FY18 Outlook
Phibro provided its fiscal 2018 guidance. The company currently expects to generate net sales of $765-$790 million. The current Zacks Consensus Estimate of $777.1 million falls within the guided range.
Phibro provided its adjusted EPS guidance in the range of $1.55–$1.61. The current Zacks Consensus Estimate of $1.55 is at the lower end of the company's guided range.
Our Take
Phibro ended the fiscal fourth quarter on a solid note with both net sales and adjusted earnings beating the Zacks Consensus Estimate. Also, the year-over-year increase on both the fronts is encouraging. Further, the company witnessed year-over-year improvement across all segments. We are also encouraged by the expansion in the gross and operating margin in the reported quarter.
Moreover, on a full-year basis, adjusted earnings and net sales have surpassed the Zacks Consensus Estimate as well with year-over-year increases in both.
The company has provided its fiscal 2018 guidance for both net sales and adjusted earnings.
Zacks Rank & Peer Performance
Phibro currently has a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corp. (EW - Free Report) , PetMed Express, Inc. (PETS - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while PetMed and IDEXX carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences’ second-quarter 2017 adjusted earnings improved 42.1% year over year, primarily driven by strong sales growth at the company’s transcatheter heart valves business. The stock has gained around 3.5% over the last three months.
IDEXX Laboratories recorded second-quarter 2017 EPS of 95 cents, up 28% (up 30% at CER year over year on a reported basis. Moreover, revenues rose 9% year over year (10% on organic basis) to $509 million.
PetMed reported earnings per share of 45 cents for the first quarter of fiscal 2018, up 40.6% from the year-ago quarter’s 32 cents. Moreover, net sales in the reported quarter rose 9.9% year over year to $79.7 million.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Learn more >>